Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Evaxion A/S EVAX

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.5M
▲ 125.1% YoY
$-7.7M
$-6.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 7.5M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.5 · Net income -7.7
3M6M-10M-20M
2018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−102 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -122.7% · Net -102.4%
-10000%-20000%-30000%
201820212025
ROE
FY2022 · ROE -113.7%
-50%-100%-150%
201820212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -57%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -6.6
-10M-20M
201820212025

Total assetsUSD 28.4M
CashUSD 23.2M
Gross debtUSD 5.5M
Net debtUSD -17.7M
Current ratio5.85×

Net debt stands at -104% of equity.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
EVAX, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.0◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌
Income tax $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌−0.81−0.98−1.26−0.97−0.81◌
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %———−113.7−124.3−183.1——
Shares out B0.42◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 29 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code G7
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image